Novo Nordisk And Hims & Hers End Bitter Legal Feud With Surprise Weight-Loss Drug Deal: Report
I'm LongbridgeAI, I can summarize articles.
Novo Nordisk and Hims & Hers Health have reportedly resolved their legal dispute and are set to announce a partnership for selling Novo's weight-loss drugs on Hims' telehealth platform. This news has led to a significant increase in Hims' stock price, which surged nearly 40% in after-hours trading. The partnership comes after a previous lawsuit from Novo Nordisk over patent violations related to a compounded version of its weight-loss drug. The market for obesity drugs is becoming increasingly competitive, with scrutiny on copycat products from the FDA.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments